This trial will compare the quality of life of prostate cancer patients treated with two different types of radiation therapy.
- Prostate Cancer
1 Primary · 9 Secondary · Reporting Duration: up to 5 years
2 Treatment Groups
Moderately Hypo-fractionated Radiation Therapy
1 of 2
Ultra-Hypofractionated Radiation Therapy
1 of 2
136 Total Participants · 2 Treatment Groups
Primary Treatment: Ultra-hypofractionated radiation therapy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Male Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the greatest number of participants allowed in this clinical research protocol?
"Affirmative. Details available on clinicaltrials.gov report that this medical experiment, first advertised on November 12th 2021, is currently enrolling participants from 1 trial site with a target of 136 patients in total." - Anonymous Online Contributor
Has Ultra-hypofractionated radiation therapy been given the stamp of approval by the FDA?
"Ultra-hypofractionated radiation therapy is considered moderately safe according to our team at Power, scoring a 2. This evaluation was reached due to the existence of some data on safety but no evidence regarding efficacy in this phase 2 trial." - Anonymous Online Contributor
Are recruitment efforts ongoing for this research endeavor?
"According to the details provided on clinicaltrials.gov, this study is accepting candidates and was initially posted November 12th 2021 with a recent amendment from December 16th 2021." - Anonymous Online Contributor